Secretin: ChiRhoStim pancreatic function test hormone
A natural gut hormone released when stomach acid enters the small intestine; triggers the pancreas to release digestive fluid; FDA-approved as ChiRhoStim for pancreatic function testing.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
What this is
Secretin is a 27-amino acid gastrointestinal peptide hormone secreted by S cells of the duodenum in response to luminal acidification. It is the oldest hormone to have been discovered in the modern sense: in 1902, William Maddock Bayliss and Ernest Henry Starling demonstrated that an extract from duodenal mucosa — when injected intravenously into a dog — stimulated pancreatic juice secretion even after all neural connections to the pancreas had been severed, coining the term "hormone" for this class of blood-borne chemical messengers. Secretin belongs to the secretin-glucagon superfamily (alongside glucagon, GLP-1, GIP, VIP, and others) and acts via the secretin receptor (SCTR), a class B G-protein-coupled receptor on pancreatic ductal cells, biliary epithelium, and central nervous system. Its primary physiological role is to stimulate secretion of a high-volume, bicarbonate-rich fluid from pancreatic ductal cells and bile ducts in response to duodenal acidification, neutralizing gastric chyme and creating the alkaline environment required for pancreatic enzyme function.
Synthetic human secretin (brand name ChiRhoStim; also Secretin-Ferring in some markets) is FDA-approved for two diagnostic indications: (1) stimulation of pancreatic secretions to aid in the diagnosis of pancreatic exocrine dysfunction, and (2) stimulation of gastrin secretion to aid in the identification of patients with gastrinoma (Zollinger-Ellison syndrome). Secretin has no approved therapeutic indications as of 2026. A period of intense interest in secretin as a potential autism treatment (following a 1998 case report) was definitively resolved by multiple randomized controlled trials and a 2011 Pediatrics systematic review showing no benefit beyond placebo (Krishnaswami and colleagues 2011).
The stored sequence — HSDGTFTSELSRLRDSARLQRLLQGLV — is the canonical 27-amino acid human secretin. Human and porcine secretin differ at position 15 (Arg in human, His in porcine); the two sequences are otherwise identical. Early clinical formulations used porcine-derived secretin; current ChiRhoStim is synthetic human secretin and is the standard for diagnostic use.
History
The discovery of secretin in 1902 by Bayliss and Starling at University College London was paradigm-shifting: it established that coordinated physiological responses could be mediated by blood-borne chemical signals without requiring neural connections — the founding demonstration of endocrinology as a discipline. Starling coined the word "hormone" (from the Greek ὁρμᾶν, to set in motion) specifically to describe secretin and related substances.
The S cells of the duodenal and jejunal mucosa release secretin in response to luminal acidification (pH below 4.5), with maximal secretion at pH 3 or below. This acid stimulus occurs physiologically as gastric chyme — acidified by HCl — enters the duodenum from the pylorus. Secretin then travels through the portal circulation to reach pancreatic ductal cells and bile duct epithelium, where it triggers bicarbonate and water secretion that alkalinizes the duodenal lumen. The resulting pH neutralization is critical for activation of pancreatic enzymes (which require pH 6–8 to function) and for enterocyte absorption.
The peptide structure of secretin was elucidated by Jorpes and Mutt in 1966. Clinical use as a diagnostic agent was established through the mid-20th century, with pancreatic secretin stimulation testing becoming a reference standard for evaluating exocrine pancreatic insufficiency. ChiRhoStim (human synthetic secretin) received FDA approval for diagnostic use. The major post-2000 episode in secretin research was the autism hypothesis: in 1998, Victoria Horvath and colleagues published a case series suggesting that secretin infusion during endoscopy improved autistic behaviors in three children, triggering widespread patient and media demand for secretin therapy. Subsequent placebo-controlled trials uniformly showed no benefit over placebo for autism spectrum disorder, and a 2011 systematic review in Pediatrics definitively established that secretin is not effective for ASD (Krishnaswami and colleagues 2011).
What it does
Secretin acts via the secretin receptor (SCTR), a class B GPCR that couples to Gαs. Receptor activation generates cAMP and PKA activation, which phosphorylates and opens the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel on the apical surface of pancreatic ductal cells and biliary epithelium. The resulting chloride efflux drives paracellular bicarbonate secretion and water flux via aquaporin channels, producing the alkaline, electrolyte-rich pancreatic juice that dilutes and neutralizes enzyme-rich acinar cell secretion.
Key physiological effects of secretin:
Pancreatic ductal secretion: The dominant effect. Secretin drives secretion of a high-volume, bicarbonate-rich fluid that alkalinizes the duodenum and provides the aqueous vehicle for digestive enzymes. This is the basis for the secretin stimulation test: a bolus secretin injection produces a measurable increase in duodenal bicarbonate output proportional to ductal cell mass and function (Chey and Chang 2014).
Biliary secretion (choleresis): Secretin acts on bile duct epithelium (cholangiocytes) via SCTR to stimulate bicarbonate-rich bile secretion — analogous to its pancreatic ductal effect. This choleretic effect is relevant to biliary tract diseases.
Gastric acid inhibition: Secretin inhibits gastrin release from G cells and directly inhibits parietal cell acid secretion, providing a physiological brake on gastric acid as chyme enters the duodenum. In Zollinger-Ellison syndrome (gastrinoma), paradoxically, secretin injection stimulates gastrin release from gastrinoma cells — the basis for the secretin stimulation test for gastrinoma.
Central nervous system effects: SCTR is expressed in the cerebellum, hypothalamus, and brainstem, and secretin acts as a neuropeptide in the CNS. Its roles include modulation of water homeostasis (interacting with vasopressin pathways) and social behavior in preclinical models. These CNS effects motivated the autism hypothesis, though RCT evidence did not support clinical benefit (Krishnaswami and colleagues 2011).
Evidence
- Secretin physiology and pancreatic function (Chey and Chang 2014, Pancreas): This comprehensive review synthesizes decades of secretin research, including definitive in vivo evidence that secretin acts as a circulating hormone. Key finding: when antisecretin antiserum was administered to eliminate circulating free secretin, postprandial pancreatic bicarbonate secretion was markedly suppressed, while gastric acid secretion increased — establishing secretin's genuine physiological role as the primary duodenal-acid-responsive hormonal stimulus for pancreatic bicarbonate secretion. The review covers the secretin stimulation test methodology, dose-response relationships, normal bicarbonate output thresholds, and the diagnostic performance of the test for chronic pancreatitis and pancreatic exocrine insufficiency. The secretin-gastrin paradoxical response in gastrinoma patients (gastrin rises instead of falls) is described as the mechanistic basis for the FDA-approved gastrinoma localization use.
- Secretin for autism — systematic review (Krishnaswami and colleagues 2011, Pediatrics): Following the Horvath 1998 case report, at least 16 randomized controlled trials evaluated secretin (single or repeated doses, intravenous or subcutaneous) for autism spectrum disorder across a range of endpoints (behavioral scales, language, social function, GI symptoms). This systematic review of those trials, conducted for the Agency for Healthcare Research and Quality, found no statistically significant benefit of secretin over placebo for any primary autism outcome measure — including the Autism Behavior Checklist, Childhood Autism Rating Scale, and caregiver-reported GI symptoms. Adverse events with secretin were minimal and consistent with its known safety profile. Conclusion: secretin is not effective for autism spectrum disorders.
Myths and misconceptions
- "Secretin treats autism" — This hypothesis arose from a 1998 case series of three children in whom secretin infusion during diagnostic endoscopy appeared to be followed by behavioral improvement. Multiple subsequent RCTs (at least 16 by 2011 count) found no benefit over placebo for autism spectrum disorder across behavioral, language, and social endpoints. The 2011 Pediatrics systematic review is definitive: secretin does not treat autism (Krishnaswami and colleagues 2011). The continued appearance of secretin in autism treatment discussions reflects persistence of the 1998 case report in patient communities, not scientific evidence.
- "Secretin is a treatment for pancreatic insufficiency" — Secretin's FDA-approved use is diagnostic, not therapeutic. The secretin stimulation test measures pancreatic bicarbonate output as an index of ductal cell function and mass, helping to diagnose chronic pancreatitis and pancreatic exocrine insufficiency. Secretin is not approved or established as a replacement therapy for pancreatic insufficiency; pancreatic enzyme replacement therapy (PERT) is the standard treatment.
- "Secretin is the same as the secretin stimulation test used for pancreatic MRI" — Secretin-enhanced MRCP (magnetic resonance cholangiopancreatography) is a related diagnostic procedure that uses IV secretin to dilate the pancreatic duct and increase pancreatic fluid output, improving visualization of the ductal system. This is a different application of the same peptide (ChiRhoStim), not a distinct drug. Both are FDA-approved diagnostic applications of human secretin (Chey and Chang 2014).
Common questions
Why did the autism secretin hypothesis gain such traction if it was wrong? The Horvath 1998 case report coincided with rapidly growing awareness of autism diagnoses in the late 1990s and a period of intense parental search for effective treatments. The n-of-3 report was widely publicized in media before rigorous follow-up studies were completed. The placebo effect in autism interventional trials is substantial (particularly for behavioral endpoints rated by caregivers), making preliminary impressions unreliable. The secretin-autism experience is frequently cited as a lesson in evidence-based medicine: dramatic-appearing single case reports must be validated by double-blind, placebo-controlled trials before adoption in practice.
What is the secretin stimulation test and how is it used clinically? The test is performed by administering IV secretin and collecting duodenal secretions at baseline and at intervals post-injection via a nasoduodenal catheter. Peak bicarbonate concentration at or above the normal threshold is the key diagnostic measure; concentrations below this threshold suggest chronic pancreatitis or pancreatic exocrine insufficiency. The test is the gold standard for quantifying exocrine function but is technically demanding and performed at specialized centers. It is now more commonly ordered in conjunction with secretin-enhanced MRCP to simultaneously image the duct and measure function (Chey and Chang 2014).
How does secretin interact with cholecystokinin (CCK) in digestion? CCK and secretin act synergistically in postprandial digestion. CCK (released from I cells in response to fat and protein in the duodenum) primarily stimulates pancreatic enzyme secretion from acinar cells and gallbladder contraction; secretin drives bicarbonate-rich fluid secretion from ductal cells. Together they coordinate the full digestive pancreatic response: enzyme-rich acinar secretion (CCK-driven) diluted and alkalinized by bicarbonate-rich ductal secretion (secretin-driven), producing the bicarbonate-buffered pancreatic juice that reaches the duodenum.
Regulatory status
- US: Prescription-only. ChiRhoStim (synthetic human secretin) is FDA-approved for stimulation of pancreatic secretions to aid diagnosis of pancreatic exocrine dysfunction and for stimulation of gastrin secretion to aid identification of gastrinoma (Zollinger-Ellison syndrome). No therapeutic indications approved.
- EU: Secretin-Ferring has been used in European markets as a diagnostic agent. Not approved for autism spectrum disorder.
Related peptides
- Glucagon — same secretin-glucagon superfamily; GCGR agonist; glycogenolysis and emergency glucose regulation
- VIP (Vasoactive Intestinal Peptide) — same family; neuropeptide with similar class B GPCR signaling; smooth muscle relaxation, vasodilation
- Semaglutide — GLP-1 agonist; same secretin-glucagon family through evolutionary origin; primary indication diabetes/obesity
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
If a hormone the gut already makes could stack on top of today's cystic fibrosis drugs, could it fix more of the pancreas damage those drugs miss?
Many people with CF still have poor digestion even on the newer modulator drugs because the pancreas does not release enough digestive fluid. If this idea holds, a long-acting version of a naturally occurring gut hormone called secretin could be given alongside existing CF drugs to squeeze more function out of the pancreas, reducing reliance on enzyme supplements and improving nutrition for a broader group of CF patients.
Is there a molecular off-switch inside pancreatic cells that muffles the hormone telling them to secrete, and could blocking it improve digestion?
The hormone galanin appears to dampen the pancreas response to secretin. If the interference happens inside the ductal cells themselves (not through nerves or neighboring cells), then a drug that blocks galanin's receptor on those cells could amplify the pancreas response to its natural stimulation. For people with conditions causing poor pancreatic output, that combination approach could mean meaningfully better digestion.
Could keeping bile ducts coated with a natural protective layer, driven by a hormone, slow the scarring disease that destroys them?
Primary sclerosing cholangitis (PSC) is a progressive bile duct disease with no approved therapy that changes its course. The bile ducts normally protect themselves with a thin bicarbonate layer; secretin appears to maintain that layer. If a longer-acting version of secretin could restore and sustain this protection, it might slow the damage and disease progression for the roughly 30,000 people in the US living with PSC.
Could large amounts of secretin accidentally mimic glucagon, the hormone that raises blood sugar, and cause unexpected metabolic side effects?
Secretin and glucagon are structurally similar enough that at high concentrations secretin might weakly activate glucagon's receptor, potentially causing blood-sugar fluctuations. Knowing this off-target risk matters most if secretin is ever developed as a regular therapy rather than just a one-off diagnostic tool. Mapping exactly where this cross-reactivity starts would help drug developers set safe dose limits and could also point toward intentional dual-purpose secretin analogs designed for metabolic conditions.
Can small changes at the end of the secretin molecule make it act only on the pancreas and bile ducts, without triggering unrelated effects in the lungs or blood vessels?
Secretin belongs to a family of hormones that all look similar and can accidentally activate each other's receptors, causing side effects like blood vessel dilation or airway changes. If just one or two positions near the tail of the secretin molecule control which receptor it locks onto, chemists could design a tightly targeted version, one that helps the pancreas or bile ducts without the off-target effects that would otherwise limit its use as a drug.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.8600478768348694 | openfold3-mlx |
| ranking score | 0.9159236550331116 | openfold3-mlx |
▸structural qualityopenfold3
| metric | value | note |
|---|---|---|
| gpde | 0.698 | global PDE — lower = better |
| disorder | 0.161 | fraction disordered |
| chain pair ipTM (A, B) | 0.860 | interface quality |
▸3-letter notation
▸recipeopenfold3-mlx 0.3.1
| parameter | value |
|---|---|
| model | openfold3-mlx 0.3.1 |
| weights | aedd8f3eb814e392… |
| hardware | apple_m4_base_16gb |
| mlx version | 0.31.1 |
| python | 3.14.3 |
| random seed | 42 |
| msa strategy | colabfold |
| diffusion samples | 1 |
| runtime | 372s |
| predicted by | mlx@peptide |
| predicted at | 2026-04-22 |
python3 openfold3/run_openfold.py predict --query_json {query.json} --runner_yaml examples/example_runner_yamls/mlx_runner.yml --output_dir {output_dir} --num_diffusion_samples 1 ▸citationbibtex
@peptide{pep04428,
sequence = {HSDGTFTSELSRLRDSARLQRLLQGLV},
target = {sctr},
author = {peptidemodel},
year = {2026},
status = {bioassayed}
}